MatthewLee,FawziAbu Rous,AlainBorczuk,StephenLiu,ShirishGadgeel,BalazsHalmos
Targeting Oncogenic Driver Mutations in Lung Cancer
Targeting Oncogenic Driver Mutations in Lung Cancer
đź’Ž Earn 84 Points (ÂŁ0.84) on this item.
We can order this item for you. Delivery usually takes about 4 to 6 weeks.
This item is not held in our immediate stock. We will order it for you after checkout.
Estimated delivery: About 4 to 6 weeks
YOU SAVE ÂŁ1.01
- Condition: Brand new
- UK Delivery times: Usually arrives within 2 - 3 working days
- UK Shipping: Fee starts at ÂŁ3.89. Subject to product weight & dimension
Bulk ordering. Want 15 or more copies? Get a personalised quote and bigger discounts. Learn more about bulk orders.
Couldn't load pickup availability
- More about Targeting Oncogenic Driver Mutations in Lung Cancer
The recent advances in molecular diagnostic techniques have identified targetable alterations in non-small cell lung cancer (NSCLC), leading to a paradigm shift in precision oncology. This Element highlights the most clinically relevant oncogenic drivers, their management, and current advancements in treatment. It also examines the challenges in resistance to targeted therapies and diagnostic dilemmas.
Format: Paperback / softback
Length: 75 pages
Publication date: 02 February 2023
Publisher: Cambridge University Press
The recent breakthroughs in molecular diagnostic techniques have brought about a significant shift in the management of non-small cell lung cancer (NSCLC), ushering in an era of precision oncology. These advancements have identified targetable alterations, leading to a paradigm change in the treatment approach. This Element focuses on highlighting the most clinically relevant oncogenic drivers beyond EGFR, their management, and the latest advancements in treatment. It also delves into the challenges associated with resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver. Furthermore, it explores the future direction of NSCLC management and the potential for personalized and targeted therapies to revolutionize the field.
The recent advancements in molecular diagnostic techniques have revolutionized the management of non-small cell lung cancer (NSCLC). These breakthroughs have identified targetable alterations, leading to a paradigm shift in the treatment approach. This Element focuses on highlighting the most clinically relevant oncogenic drivers beyond EGFR, their management, and the latest advancements in treatment. It also delves into the challenges associated with resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver. Furthermore, it explores the future direction of NSCLC management and the potential for personalized and targeted therapies to revolutionize the field.
The recent breakthroughs in molecular diagnostic techniques have transformed the landscape of non-small cell lung cancer (NSCLC) management. These advancements have identified targetable alterations, leading to a paradigm shift in the treatment approach. This Element highlights the most clinically relevant oncogenic drivers beyond EGFR, their management, and the latest advancements in treatment. It also delves into the challenges associated with resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver. Furthermore, it explores the future direction of NSCLC management and the potential for personalized and targeted therapies to revolutionize the field.
The recent advancements in molecular diagnostic techniques have revolutionized the management of non-small cell lung cancer (NSCLC). These breakthroughs have identified targetable alterations, leading to a paradigm shift in the treatment approach. This Element focuses on highlighting the most clinically relevant oncogenic drivers beyond EGFR, their management, and the latest advancements in treatment. It also delves into the challenges associated with resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver. Furthermore, it explores the future direction of NSCLC management and the potential for personalized and targeted therapies to revolutionize the field.
ISBN-13: 9781009336130
UK and International shipping information
UK and International shipping information
We deliver throughout the United Kingdom and to 128 countries and territories worldwide, including the United States, Australia, Canada, Germany, Spain and France.
